STOCK TITAN

REDWOOD SCIENTIFIC TECH - RSCI STOCK NEWS

Welcome to our dedicated page for REDWOOD SCIENTIFIC TECH news (Ticker: RSCI), a resource for investors and traders seeking the latest updates and insights on REDWOOD SCIENTIFIC TECH stock.

Redwood Scientific Technologies Inc. (RSCI), headquartered in New York, is a pioneering pharmaceutical company renowned globally for its innovative drug delivery systems, particularly through oral thin film strips. With a robust focus on research and development, the company has established itself as a leader in addressing lifestyle-related health issues.

Redwood's flagship product, TBX-FREE, is an FDA-registered over-the-counter aid designed to help individuals overcome nicotine addiction. Utilizing advanced sublingual delivery methods, Redwood's oral thin film strips provide a more efficient and user-friendly alternative to traditional nicotine replacement therapies. The company's products are listed in the National Drug Directory, underscoring their legitimacy and accessibility.

The company has a diverse product pipeline set to be released over the next four years, including solutions for sleep aids and men's sexual dysfunction. Redwood is also developing a complete product line for children, starting with a child-friendly oral thin film version of ibuprofen.

Redwood's market strategy emphasizes direct-to-consumer sales, complemented by partnerships with large wholesale distributors. Recent achievements include the filing of a patent for a cutting-edge Oral Thin Film (OTF) manufacturing system that enhances dosage accuracy and bioavailability, revolutionizing drug delivery mechanisms. The company is actively collaborating with global research groups to validate the efficacy of its products, including TBX-FREE, through comprehensive clinical trials and studies.

Key recent developments include:

  • Filing of a new patent for an advanced OTF manufacturing system.
  • Conditional approval for clinical studies on products addressing nicotine addiction in vape devices.
  • Finalization of flavors for TBX VAPE FREE, a nicotine-free vape cessation strip.
  • Engagement with George Mason University for a clinical effectiveness study on TBX-FREE.
  • Strategic plans to establish a manufacturing hub in the US to reduce dependency on foreign-sourced pharmaceutical goods.

Redwood Scientific Technologies remains committed to advancing healthcare through innovative solutions, precision in drug delivery, and rigorous scientific research, aiming to provide accessible and effective treatments that improve patient outcomes and quality of life.

Rhea-AI Summary

Redwood Scientific Technologies announced the finalization of five flavors for its TBX VAPE FREE strips, aimed at helping users quit vaping by providing a similar sensory experience. The product is nicotine-free and designed to meet vape users' preferences through advanced technology. This announcement comes after a Daily Mail article highlighted the dangers of vaping. Jason Cardiff, the founder and President, expressed confidence in the product's market reception and emphasized the urgency of addressing the vaping epidemic. The company plans to bring TBX VAPE FREE to market soon.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.09%
Tags
none
-
Rhea-AI Summary

Redwood Scientific Technologies (RSCI) announced the finalization of five flavors for its TBX VAPE FREE strips, aiming to pioneer the vape cessation category. Following a double-blind, randomized, placebo-based scientific study, production will ramp up to millions of strips per month to meet anticipated high demand. The product offers a sensory experience similar to vaping but without nicotine. This announcement follows a Daily Mail story highlighting the dangers of vaping. Christina Hayes resigned from the Board of Directors on April 14, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.09%
Tags
none
-
Rhea-AI Summary
Redwood Scientific Technologies Inc. (OTC: RSCI) announced a strategic shift in product development to focus on enhancing nicotine replacement therapy products TBX-FREE™ and TBX VAPE-FREE™. This decision follows research linking e-cigarette use to heart failure risks, emphasizing the need for safer alternatives.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
37.36%
Tags
none
Rhea-AI Summary
Redwood Scientific Technologies Inc. (RSCI) achieved significant milestones in 2023, focusing on innovative pharmaceutical products. CEO Jason Cardiff is leading the company's initiative to establish an oral thin film manufacturing hub in the US, aiming for self-reliance. Redwood plans to transition to the OTCQB platform in April 2024, after submitting an application for NASDAQ listing. Key highlights include financial audit completion, patent approvals, product launch readiness, and partnerships for clinical testing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.67%
Tags
none
-
Rhea-AI Summary
Redwood Scientific Technologies Inc. has engaged George Mason University to conduct a clinical effectiveness study of its TBX-Free oral strips for smoking and e-cigarette cessation. The company aims to bring a nicotine-free product to market to help millions of adults and youths overcome nicotine addiction. The TBX-Free oral strips rely on the power of cytisine, a more effective active ingredient than nicotine, found in golden rain trees. The company is committed to developing safe and effective products to address the crisis of nicotine addiction, especially among youth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
45.19%
Tags
-
Rhea-AI Summary
Redwood Scientific Technologies (RSCI OTC PINK) has secured conditional approval from the Institutional Review Board (IRB)/Central Institutional Review Board (CIRB) for groundbreaking clinical studies on a new Oral Thin Film Strip to address nicotine addiction in vape devices and TBX FREE for traditional cigarettes. This milestone signifies a significant advancement in Redwood's efforts to combat nicotine addiction and marks a crucial step forward in bringing nicotine-free solutions to the market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.98%
Tags
Rhea-AI Summary
Redwood Scientific Technologies successfully files S1 registration statement with the SEC and provides updates on clinical trial progress for TBX FREE and TBX VAPE FREE.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Redwood Scientific Technologies Inc. corrects a previous press release, clarifying that the arrangement with Silk Road Ent., Inc. was a 'Marketing Consulting Agreement' and not a partnership. Redwood has canceled the agreement and prohibited Silk Road from marketing or selling its premarket development products. CEO Jason Cardiff expresses confidence in regulatory compliance and establishing beneficial partnerships.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Redwood Scientific Technologies Inc. files a new patent for its Oral Thin Film (OTF) manufacturing system, aiming to revolutionize the pharmaceutical industry. The system offers precise administration of nano dosages of active ingredients, enhancing bioavailability and patient outcomes. Redwood is also working on an effectiveness study for its flagship product, TBX-FREE, with promising feedback from customers. The study results are expected to be published in the fourth quarter of this year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20%
Tags
none

FAQ

What is the current stock price of REDWOOD SCIENTIFIC TECH (RSCI)?

The current stock price of REDWOOD SCIENTIFIC TECH (RSCI) is $0.3269 as of October 10, 2024.

What is the market cap of REDWOOD SCIENTIFIC TECH (RSCI)?

The market cap of REDWOOD SCIENTIFIC TECH (RSCI) is approximately 69.4M.

What does Redwood Scientific Technologies Inc. specialize in?

Redwood Scientific Technologies Inc. specializes in innovative drug delivery systems, particularly through oral thin film strips, targeting lifestyle-related health issues.

What is TBX-FREE?

TBX-FREE is an FDA-registered over-the-counter aid developed by Redwood Scientific Technologies to help individuals overcome nicotine addiction using sublingual thin film delivery.

What are some recent achievements of Redwood Scientific Technologies?

Recent achievements include the filing of a new patent for their Oral Thin Film manufacturing system, the finalization of TBX VAPE FREE flavors, and conditional approval for clinical studies on nicotine addiction solutions.

What products are in Redwood's pipeline?

Redwood's product pipeline includes aids for sleep and men's sexual dysfunction, a children's line starting with ibuprofen thin film strips, and various nicotine cessation products like TBX VAPE FREE.

Who are Redwood's target customers?

Redwood targets direct-to-consumer sales and large wholesale distributors, focusing on individuals seeking innovative solutions for lifestyle-related health issues.

What is the new patent filed by Redwood about?

The new patent is for an advanced Oral Thin Film manufacturing system that enhances dosage accuracy and bioavailability, improving drug delivery efficiency.

What clinical trials are Redwood currently involved in?

Redwood is conducting clinical trials for TBX-FREE and TBX VAPE FREE to validate their efficacy in nicotine addiction treatment, in collaboration with George Mason University and other research groups.

What is the significance of Redwood's new manufacturing hub initiative?

The new manufacturing hub in the US aims to reduce dependency on foreign-sourced pharmaceutical goods, ensuring self-reliance and streamlined production processes.

Are Redwood's products FDA-registered?

Yes, all Redwood products, including TBX-FREE, are FDA-registered and listed in the National Drug Directory.

How can I contact Redwood Scientific Technologies for more information?

For more information, you can visit their website at www.redwoodsci.co or contact them via email at info@redwoodsci.co or phone at 646-503-7884.

REDWOOD SCIENTIFIC TECH

OTC:RSCI

RSCI Rankings

RSCI Stock Data

69.42M
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States of America
Claremont